Cyclophosphamide's addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide-dexamethasone treatment.

Laura CesiniAgostina SiniscalchiSara GrammaticoAlessandro AndrianiAlessia FioriniLuca De RosaTommaso ZaAngela RagoTommaso CaravitaMaria Teresa Petrucci

Published in: European journal of haematology (2018)

The addition of cyclophosphamide delays the progression in patients who present a biochemical relapse during Rd treatment. The response rate and the duration of PFS obtained with minimal toxicities and low costs induced us to setting up a randomized clinical trial.

Keyphrases

multiple myeloma
low dose
high dose
acute myeloid leukemia
acute lymphoblastic leukemia
high glucose
oxidative stress
newly diagnosed
combination therapy